Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Nectar Lifesciences Ltd

NECLIFE

Nectar Lifesciences Ltd

NECLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹820 cr, stock is ranked 1,573
High RiskStock is 4.24x as volatile as Nifty
36.592.01% (-0.75)
36.592.01% (-0.75)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹820 cr, stock is ranked 1,573
High RiskStock is 4.24x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹820 cr, stock is ranked 1,573
High RiskStock is 4.24x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
133.860.77—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -9.44%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.27% to 0.45%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -36.31%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,681.461,666.371,882.292,788.912,370.701,547.081,680.151,566.851,698.661,663.91
Raw Materialssubtract1,198.701,145.851,417.322,268.131,862.831,052.821,207.321,200.841,242.451,493.45
Power & Fuel Costsubtract87.8975.4491.85103.4792.7284.63101.41127.39129.52
Employee Costsubtract78.3875.5474.6576.5478.1970.5971.9175.1481.71
Selling & Administrative Expensessubtract56.5459.9852.2367.9967.0172.0466.8662.6461.39
Operating & Other expensessubtract15.4462.484.062.5645.89179.4962.794.6617.46
Depreciation/Amortizationsubtract57.3962.2564.3163.2660.7760.2556.9759.1260.7260.84
Interest & Other Itemssubtract123.31117.41115.20148.14125.83112.0478.8179.4987.1489.50
Taxes & Other Itemssubtract9.5912.0810.4111.225.68-11.509.03-18.2413.2813.99
EPS2.422.472.332.121.42-3.271.12-1.080.220.27
DPS0.100.050.050.050.050.000.000.000.000.00
Payout ratio0.040.020.020.020.040.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nectar Lifesciences Ltd164.440.77—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare NECLIFE with any stock or ETF
Compare NECLIFE with any stock or ETF
NECLIFE
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 11.45%

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.31%

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 14.03%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.35%0.00%0.00%2.57%53.07%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep15.99%12.73%16.11%16.97%16.61%2.57%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 11, 2020

Final
Final | Div/Share: ₹0.05

Dividend/Share

₹0.05

Ex DateEx Date

Sep 11, 2020

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.05

Dividend/Share

₹0.05

Ex DateEx Date

Sep 19, 2019

Cash Dividend

Ex DateEx DateSep 19, 2018

Final
Final | Div/Share: ₹0.05

Dividend/Share

₹0.05

Ex DateEx Date

Sep 19, 2018

Cash Dividend

Ex DateEx DateSep 20, 2017

Final
Final | Div/Share: ₹0.05

Dividend/Share

₹0.05

Ex DateEx Date

Sep 20, 2017

Cash Dividend

Ex DateEx DateSep 22, 2016

Final
Final | Div/Share: ₹0.10

Dividend/Share

₹0.10

Ex DateEx Date

Sep 22, 2016

News & Opinions
Corporate
Nectar Lifescience schedules board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Nectar Lifescience to conduct AGM

Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Nectar Lifescience to convene AGM

Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 63.19% in the June 2024 quarter

Net profit of Nectar Lifescience rose 63.19% to Rs 2.97 crore in the quarter ended June 2024 as against Rs 1.82 crore during the previous quarter ended June 2023. Sales declined 8.95% to Rs 358.85 crore in the quarter ended June 2024 as against Rs 394.12 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales358.85394.12 -9 OPM %11.099.02 - PBDT20.3818.39 11 PBT4.923.06 61 NP2.971.82 63 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Nectar Lifescience to conduct board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Nectar Lifesciences' Dinesh Dua Speaks On Impact Of ATD Levied On Key Products | Chartbusters
3 years agoCNBC-TV18

Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans

3 years agoIndia Infoline
Circuit limits changed for 546 stocks
3 years agoET NOW
NECTAR LIFESCIENCES है मजबूती वाला Stock?, जानें क्या है खरीदारी पर राय? | Seedha Sauda | CNBC Awaaz
3 years agoCNBC Awaaz

Nectar Lifesciences board opt for one-time debt restructuring

3 years agoThe Hindu Businessline